Learn about the top trends and technologies in psychedelic therapeutics|Amy Kruse,General Partner,Prime Movers Lab 00:10:00
Amy Kruse is a General Partner of Prime Movers Lab where she leads our life sciences investments. As a neuroscientist and biologist, she discovers emerging new companies and leads in-depth due diligence into potential investments across areas including neuroscience, human augmentation, synthetic biology, longevity/regeneration, and agriculture. She also supports portfolio companies in evaluating and overcoming scientific and implementation challenges, with a specific emphasis on deploying complex technology into real-world environments. Amy is formerly the Chief Scientific Officer at Optios, an applied neuroscience company. She built the company’s scientific vision and completed acquisitions that resulted in a robust intellectual property portfolio. Amy also served as the VP and CTO at Cubic Global Defense overseeing innovation and the R&D portfolio across the entire defense enterprise.